These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 9617787)

  • 81. Reduced brain delivery of homovanillic acid to cerebrospinal fluid during human aging.
    Rapoport SI; Schapiro MB; May C
    Arch Neurol; 2004 Nov; 61(11):1721-4. PubMed ID: 15534183
    [TBL] [Abstract][Full Text] [Related]  

  • 82. CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease.
    Gibson CJ; Logue M; Growdon JH
    Arch Neurol; 1985 May; 42(5):489-92. PubMed ID: 2581531
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.
    Martignoni E; Blandini F; Godi L; Desideri S; Pacchetti C; Mancini F; Nappi G
    Free Radic Biol Med; 1999 Aug; 27(3-4):428-37. PubMed ID: 10468218
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Study on dopamine metabolite in cerebrospinal fluid of schizophrenics and epilepsics].
    Jiang S; Chen X; Liao W
    Hunan Yi Ke Da Xue Xue Bao; 1998; 23(2):155-6. PubMed ID: 10681831
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice.
    Prell GD; Khandelwal JK; Burns RS; Blandina P; Morrishow AM; Green JP
    J Neural Transm Park Dis Dement Sect; 1991; 3(2):109-25. PubMed ID: 1910485
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease.
    Liu H; Iacono RP; Schoonenberg T; Kuniyoshi S; Buchholz J
    Neurobiol Dis; 1999 Feb; 6(1):35-42. PubMed ID: 10078971
    [TBL] [Abstract][Full Text] [Related]  

  • 87. The significance of homovanillic acid and 3,4-dihydroxyphenylacetic acid concentrations in human lumbar cerebrospinal fluid.
    Ebinger G; Michotte Y; Herregodts P
    J Neurochem; 1987 Jun; 48(6):1725-9. PubMed ID: 3572399
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease.
    Vieru E; Köksal A; Mutluay B; Dirican AC; Altunkaynak Y; Baybas S
    Neurol Sci; 2016 May; 37(5):743-7. PubMed ID: 26753800
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Lower CSF homovanillic acid levels in depressed patients with a history of alcoholism.
    Sher L; Oquendo MA; Li S; Huang YY; Grunebaum MF; Burke AK; Malone KM; Mann JJ
    Neuropsychopharmacology; 2003 Sep; 28(9):1712-9. PubMed ID: 12825091
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Sex and genetic associations with cerebrospinal fluid dopamine and metabolite production after severe traumatic brain injury.
    Wagner AK; Ren D; Conley YP; Ma X; Kerr ME; Zafonte RD; Puccio AM; Marion DW; Dixon CE
    J Neurosurg; 2007 Apr; 106(4):538-47. PubMed ID: 17432702
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Cerebrospinal fluid homovanillic acid in cerebral infarction.
    Hachinski V; Shibuya M; Norris JW; Hornykiewicz O
    J Neural Transm Suppl; 1978; (14):45-50. PubMed ID: 290739
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species.
    Spencer JP; Jenner P; Daniel SE; Lees AJ; Marsden DC; Halliwell B
    J Neurochem; 1998 Nov; 71(5):2112-22. PubMed ID: 9798937
    [TBL] [Abstract][Full Text] [Related]  

  • 93. β-asarone and levodopa coadministration increases striatal levels of dopamine and levodopa and improves behavioral competence in Parkinson's rat by enhancing dopa decarboxylase activity.
    Huang L; Deng M; Zhang S; Lu S; Gui X; Fang Y
    Biomed Pharmacother; 2017 Oct; 94():666-678. PubMed ID: 28787702
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease.
    Boll MC; Sotelo J; Otero E; Alcaraz-Zubeldia M; Rios C
    Neurosci Lett; 1999 Apr; 265(3):155-8. PubMed ID: 10327154
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Analysis of neurotransmitter metabolite concentrations in canine cerebrospinal fluid.
    Vaughn DM; Coleman E; Simpson ST; Satjawatcharaphong C
    Am J Vet Res; 1988 Aug; 49(8):1302-6. PubMed ID: 2459997
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Indicators of brain biogenic amine metabolism in various extrapyramidal disorders].
    Barchatowa WP; Milewska D; Wehr H
    Neurol Neurochir Pol; 1981; 15(4):381-6. PubMed ID: 6173791
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease.
    Jiménez-Jiménez FJ; Molina JA; Aguilar MV; Meseguer I; Mateos-Vega CJ; González-Muñoz MJ; de Bustos F; Martínez-Salio A; Ortí-Pareja M; Zurdo M; Martínez-Para MC
    J Neural Transm (Vienna); 1998; 105(4-5):497-505. PubMed ID: 9720977
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
    MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
    Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Dopamine sulfate in ventricular cerebrospinal fluid and motor function in Parkinson's disease.
    Cedarbaum JM; Olanow CW
    Neurology; 1991 Oct; 41(10):1567-70. PubMed ID: 1922797
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease.
    Reinikainen KJ; Paljärvi L; Halonen T; Malminen O; Kosma VM; Laakso M; Riekkinen PJ
    Neurobiol Aging; 1988; 9(3):245-52. PubMed ID: 3398991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.